Blair William & Company Has Raised Its Nektar Therapeutics (NKTR) Stake; International Game Technology PLC (IGT) Covered By 4 Bullish Analysts Last Week

January 14, 2018 - By Maria Brooks

Among 7 analysts covering Intl Game Tech. PLC (NYSE:IGT), 4 have Buy rating, 2 Sell and 1 Hold. Therefore 57% are positive. Intl Game Tech. PLC had 19 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of International Game Technology PLC (NYSE:IGT) earned “Outperform” rating by Telsey Advisory Group on Wednesday, September 28. The stock has “Buy” rating by Union Gaming Research on Tuesday, August 18. Sterne Agee CRT downgraded the shares of IGT in report on Tuesday, August 18 to “Underperform” rating. The firm has “Sell” rating given on Wednesday, August 19 by Goldman Sachs. Bank of America maintained International Game Technology PLC (NYSE:IGT) rating on Wednesday, November 15. Bank of America has “Buy” rating and $32 target. Bank of America downgraded the stock to “Neutral” rating in Thursday, January 26 report. The firm earned “Outperform” rating on Friday, May 26 by Telsey Advisory Group. The company was downgraded on Friday, March 24 by Argus Research. The rating was upgraded by Bank of America on Wednesday, September 20 to “Buy”. Argus Research initiated the stock with “Buy” rating in Friday, September 16 report. See International Game Technology PLC (NYSE:IGT) latest ratings:

29/11/2017 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade
15/11/2017 Broker: Bank of America Rating: Buy Old Target: $30 New Target: $32 Maintain
26/09/2017 Broker: Deutsche Bank Rating: Buy New Target: $30.0 Upgrade
20/09/2017 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade

Blair William & Company increased Nektar Therapeutics (NKTR) stake by 9.12% reported in 2017Q3 SEC filing. Blair William & Company acquired 29,388 shares as Nektar Therapeutics (NKTR)’s stock rose 44.66%. The Blair William & Company holds 351,645 shares with $8.44M value, up from 322,257 last quarter. Nektar Therapeutics now has $11.34 billion valuation. The stock increased 3.03% or $2.12 during the last trading session, reaching $72. About 1.90 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since January 14, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

International Game Technology PLC operates and provides technology services and products across lotteries, electronic gaming machines, sports betting, and interactive gaming markets worldwide. The company has market cap of $5.63 billion. It designs, sells, and operates a suite of point-of-sale terminals that reconciles lottery funds between the retailer and lottery authority; provides online lottery transaction processing systems; and produces instant ticket games and offers printing services, such as instant ticket marketing plans and graphic design, programming, packaging, shipping, and delivery services. It currently has negative earnings. The firm also provides video lottery terminals , VLT central systems, and VLT games to government customers; video and traditional mechanical reel slot machines and casino systems to casino operators; and amusement with prize machines and games to licensed operators.

The stock decreased 0.86% or $0.24 during the last trading session, reaching $27.79. About 730,028 shares traded. International Game Technology PLC (NYSE:IGT) has risen 22.31% since January 14, 2017 and is uptrending. It has outperformed by 5.61% the S&P500.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Roth Capital with “Buy” on Monday, September 21. The rating was maintained by Roth Capital with “Buy” on Thursday, July 20. The firm earned “Buy” rating on Monday, June 5 by Aegis Capital. The firm has “Buy” rating given on Thursday, November 9 by Canaccord Genuity. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Wednesday, January 10 by Canaccord Genuity. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Wednesday, August 16 by Jefferies. The rating was maintained by Roth Capital with “Buy” on Monday, November 13. The rating was downgraded by TheStreet to “Hold” on Wednesday, August 26. The rating was maintained by Piper Jaffray on Thursday, January 7 with “Overweight”. The firm has “Buy” rating given on Wednesday, October 18 by Jefferies.

Investors sentiment decreased to 1.4 in 2017 Q3. Its down 0.49, from 1.89 in 2017Q2. It worsened, as 15 investors sold NKTR shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. The Massachusetts-based Putnam Investments Limited Liability Com has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Citigroup Incorporated has invested 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Brinker Cap Inc has invested 0.04% in Nektar Therapeutics (NASDAQ:NKTR). Teacher Retirement Systems Of Texas owns 12,666 shares or 0% of their US portfolio. Prelude Management Ltd Liability Corp accumulated 16,587 shares or 0.04% of the stock. Susquehanna International Gru Limited Liability Partnership holds 413,245 shares or 0% of its portfolio. Ubs Asset Americas Incorporated reported 0.01% stake. Public Employees Retirement Association Of Colorado holds 29,177 shares. Goldman Sachs Grp Inc owns 949,025 shares. Mason Street Advsr Ltd Limited Liability Company reported 39,593 shares stake. Dekabank Deutsche Girozentrale holds 0.01% or 54,400 shares in its portfolio. Principal Financial Grp Incorporated holds 1.46 million shares. Piedmont Investment Ltd Llc holds 34,053 shares. Parkside Bank & Trust Trust invested in 91 shares or 0% of the stock. Perigon Wealth Ltd Liability Corp stated it has 5,059 shares or 0.04% of all its holdings.

Since August 16, 2017, it had 0 insider buys, and 18 sales for $19.24 million activity. 4,000 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $87,440 were sold by KUEBLER CHRISTOPHER A. CHESS ROBERT had sold 6,400 shares worth $139,008. $1.09M worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Doberstein Stephen K. ROBIN HOWARD W had sold 83,333 shares worth $4.64M. 3,177 shares were sold by Nicholson John, worth $61,380 on Wednesday, August 16. Gergel Ivan P. also sold $2.41M worth of Nektar Therapeutics (NASDAQ:NKTR) shares. Another trade for 2,648 shares valued at $51,159 was sold by Thomsen Jillian B..

Blair William & Company decreased Fortinet Inc (NASDAQ:FTNT) stake by 17,302 shares to 94,559 valued at $3.39 million in 2017Q3. It also reduced Middleby Corp (NASDAQ:MIDD) stake by 18,429 shares and now owns 28,071 shares. Take (NASDAQ:TTWO) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts